Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ristabil is a multi-ingredient dietary supplement developed by Laboratoires Leurquin-Mediolanum, a subsidiary of the Mediolanum Group. It is specifically formulated to address physical and mental fatigue, asthenia, and recovery during convalescence. The product is administered as an oral liquid via 10ml drinkable vials. Its active composition includes royal jelly, Eleutherococcus (Siberian ginseng) extract for its adaptogenic properties, blueberry (Vaccinium myrtillus) extract, and wild rose (Rosa canina) extract, supplemented with vitamins B1 (thiamine), B2 (riboflavin), and B6 (pyridoxine). These components work synergistically to support energy metabolism and stress resistance. Ristabil is marketed for use in children, adults, and the elderly and is available in pharmacies across France and Italy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ristabil.